JPWO2021154828A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021154828A5 JPWO2021154828A5 JP2022572258A JP2022572258A JPWO2021154828A5 JP WO2021154828 A5 JPWO2021154828 A5 JP WO2021154828A5 JP 2022572258 A JP2022572258 A JP 2022572258A JP 2022572258 A JP2022572258 A JP 2022572258A JP WO2021154828 A5 JPWO2021154828 A5 JP WO2021154828A5
- Authority
- JP
- Japan
- Prior art keywords
- cov
- sars
- coronavirus
- polynucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 claims description 70
- 108091033319 polynucleotide Proteins 0.000 claims description 62
- 102000040430 polynucleotide Human genes 0.000 claims description 62
- 239000002157 polynucleotide Substances 0.000 claims description 62
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 108020004705 Codon Proteins 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 108010067390 Viral Proteins Proteins 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 11
- 229940096437 Protein S Drugs 0.000 claims description 10
- 101710198474 Spike protein Proteins 0.000 claims description 10
- 108060004795 Methyltransferase Proteins 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108700010070 Codon Usage Proteins 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 108090001126 Furin Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 241000494545 Cordyline virus 2 Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
- 229940100662 nasal drops Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 description 2
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966750P | 2020-01-28 | 2020-01-28 | |
| US62/966,750 | 2020-01-28 | ||
| US202063048942P | 2020-07-07 | 2020-07-07 | |
| US63/048,942 | 2020-07-07 | ||
| US202063079337P | 2020-09-16 | 2020-09-16 | |
| US63/079,337 | 2020-09-16 | ||
| US202063079853P | 2020-09-17 | 2020-09-17 | |
| US63/079,853 | 2020-09-17 | ||
| PCT/US2021/015246 WO2021154828A1 (en) | 2020-01-28 | 2021-01-27 | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519640A JP2023519640A (ja) | 2023-05-11 |
| JPWO2021154828A5 true JPWO2021154828A5 (https=) | 2024-02-06 |
| JP2023519640A5 JP2023519640A5 (https=) | 2024-02-06 |
Family
ID=77078567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572258A Pending JP2023519640A (ja) | 2020-01-28 | 2021-01-27 | 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230117167A1 (https=) |
| EP (1) | EP4096712A4 (https=) |
| JP (1) | JP2023519640A (https=) |
| KR (1) | KR20220132588A (https=) |
| CN (1) | CN115427073A (https=) |
| AU (1) | AU2021213121A1 (https=) |
| BR (1) | BR112022014700A2 (https=) |
| CA (1) | CA3168100A1 (https=) |
| CL (1) | CL2022002030A1 (https=) |
| CO (1) | CO2022010743A2 (https=) |
| IL (1) | IL295112A (https=) |
| MX (1) | MX2022009099A (https=) |
| PE (1) | PE20230166A1 (https=) |
| PH (1) | PH12022551788A1 (https=) |
| SA (1) | SA522433428B1 (https=) |
| TW (1) | TW202144570A (https=) |
| WO (1) | WO2021154828A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| CN115297892A (zh) * | 2020-02-07 | 2022-11-04 | 达冕生物有限公司 | 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 |
| WO2021177773A2 (ko) * | 2020-03-06 | 2021-09-10 | (주)지노믹트리 | Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법 |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2022011428A1 (en) * | 2020-07-16 | 2022-01-20 | Griffith University | Live-attenuated virus vaccine |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2023018831A2 (en) | 2021-08-11 | 2023-02-16 | RNAimmune, Inc. | Composition and methods of mrna vaccines against novel coronavirus infection |
| WO2023037387A2 (en) | 2021-09-08 | 2023-03-16 | Serum Institute Of India Private Limited | Freeze-dried viral combination vaccine compositions and process for preparation thereof |
| AU2022435931A1 (en) * | 2022-01-20 | 2024-07-18 | Freie Universität Berlin | A live attenuated sars-cov-2 and a vaccine made thereof |
| WO2023186946A1 (en) * | 2022-03-28 | 2023-10-05 | Universität Bern | One-to-stop attenuated sars-cov-2 virus |
| EP4331602A1 (en) * | 2022-09-05 | 2024-03-06 | Freie Universität Berlin | A live attenuated sars-cov-2 and a vaccine made thereof |
| CA3266020A1 (en) | 2022-09-05 | 2024-03-14 | Freie Universitat Berlin | LIVE ATTENUATED SARS-CoV-2 AND VACCINE MADE FROM IT |
| KR20250084962A (ko) * | 2022-10-12 | 2025-06-11 | 유니버시태트 베른 | 원-투-스톱 약독화된 SARS-CoV-2 바이러스를 사용한 치료 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| WO2025081050A1 (en) * | 2023-10-13 | 2025-04-17 | Duke University | Coronavirus stem helix and fusion peptide nanoparticle vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| DK3312272T3 (da) * | 2004-10-08 | 2019-12-02 | Us Gov Health & Human Services | Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner |
| EP4368202A3 (en) * | 2007-03-30 | 2024-08-21 | The Research Foundation for The State University of New York | Attenuated viruses useful for vaccines |
| TW201125984A (en) * | 2009-10-09 | 2011-08-01 | Univ New York State Res Found | Attenuated influenza viruses and vaccines |
| US10953083B2 (en) * | 2015-12-11 | 2021-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts |
| MX2019011599A (es) * | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| US20200299651A1 (en) * | 2017-10-16 | 2020-09-24 | Glaxosmithkline Biologicals Sa | Simian adenoviral vectors with two expression cassettes |
-
2021
- 2021-01-27 AU AU2021213121A patent/AU2021213121A1/en active Pending
- 2021-01-27 IL IL295112A patent/IL295112A/en unknown
- 2021-01-27 PE PE2022001498A patent/PE20230166A1/es unknown
- 2021-01-27 EP EP21747780.1A patent/EP4096712A4/en active Pending
- 2021-01-27 CA CA3168100A patent/CA3168100A1/en active Pending
- 2021-01-27 CN CN202180024216.XA patent/CN115427073A/zh active Pending
- 2021-01-27 KR KR1020227029265A patent/KR20220132588A/ko active Pending
- 2021-01-27 BR BR112022014700A patent/BR112022014700A2/pt unknown
- 2021-01-27 JP JP2022572258A patent/JP2023519640A/ja active Pending
- 2021-01-27 WO PCT/US2021/015246 patent/WO2021154828A1/en not_active Ceased
- 2021-01-27 US US17/794,862 patent/US20230117167A1/en active Pending
- 2021-01-27 TW TW110103098A patent/TW202144570A/zh unknown
- 2021-01-27 MX MX2022009099A patent/MX2022009099A/es unknown
- 2021-01-27 PH PH1/2022/551788A patent/PH12022551788A1/en unknown
-
2022
- 2022-07-27 SA SA522433428A patent/SA522433428B1/ar unknown
- 2022-07-28 CL CL2022002030A patent/CL2022002030A1/es unknown
- 2022-07-29 CO CONC2022/0010743A patent/CO2022010743A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021154828A5 (https=) | ||
| TW202140794A (zh) | 疫苗及其誘導對sars-cov2之免疫反應之用途 | |
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| JP2013501038A5 (https=) | ||
| KR101196178B1 (ko) | Ｈｉｖ 조절/부속 단백질의 융합 단백질 | |
| JP2014527404A5 (https=) | ||
| JP2002533124A5 (https=) | ||
| JP2017522907A5 (https=) | ||
| CN118272396A (zh) | 用于预防或治疗hpv感染相关疾病的多核苷酸分子 | |
| JP3439472B2 (ja) | ヘルペスウイルスチミジンキナーゼをコード付けするｄｎａの単離方法 | |
| US20250026793A1 (en) | Chimeric betacoronavirus spike polypeptides | |
| JP4665122B2 (ja) | 組み換えウイルスおよびその用途 | |
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| Funahashi et al. | Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses | |
| WO2023047349A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| CN116549627A (zh) | 基于腺病毒载体的广谱新冠疫苗及其应用 | |
| RU2024102863A (ru) | Деоптимизированные варианты sars-cov-2, их способы и применения | |
| WO2019145739A1 (en) | Lassa virus antigenic composition | |
| KR102616012B1 (ko) | 당화된 돼지 인터페론-알파를 발현하는 재조합 베큘로바이러스 | |
| US20250312486A1 (en) | Compositions for restoring mecp2 gene function and methods of use thereof | |
| JPWO2021198701A5 (https=) | ||
| CN116200349A (zh) | 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗 | |
| EP3922263A1 (en) | Ad7 vector vaccine for preventing sars-cov-2 infection | |
| JPWO2022010813A5 (https=) | ||
| JPWO2023150638A5 (https=) |